Please check your internet connection and try again.
## Pantoprazole
### Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
### Primary Indications
* Erosive esophagitis associated with gastroesophageal reflux disease (GERD)
* Maintenance of healing of erosive esophagitis
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome)
### Adult Dosing
* **Erosive esophagitis:** 40 mg orally once daily for 4 to 8 weeks.
* **Maintenance of healing:** 40 mg orally once daily. Doses may be increased to 40 mg twice daily for those requiring further acid suppression.
* **Pathological hypersecretory conditions:** Starting dose is 40 mg orally twice daily. Doses may be adjusted based on clinical response. The maximum recommended dose is 240 mg daily given as 40 mg three times daily.
### Pediatric Dosing
* **Erosive esophagitis (5 to 16 years):** 20 mg to 40 mg orally once daily for up to 8 weeks.
* **GERD (6 months to 16 years):** Dosing varies based on indication and weight. For erosive esophagitis: 20 mg to 40 mg once daily for up to 8 weeks. For other indications, consult specific pediatric guidelines.
### Dose Adjustments
* **Hepatic Impairment:** Maximum dose of 20 mg orally once daily.
* **Renal Impairment:** No dose adjustment necessary.
### Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
* Use of certain HIV protease inhibitors (e.g., atazanavir, nelfinavir) where gastric pH is crucial for absorption.
### Adverse Effects
* Common: Headache, diarrhea, nausea, abdominal pain, dizziness.
* Long-term use: Increased risk of bone fractures (hip, wrist, spine), *Clostridioides difficile*-associated diarrhea, vitamin B12 deficiency, hypomagnesemia.
### Key Drug Interactions
* **Drugs requiring gastric pH for absorption:** Ketoconazole, itraconazole, iron salts, vitamin B12, certain HIV protease inhibitors (e.g., atazanavir, nelfinavir). Separate administration or avoid.
* **Warfarin:** May increase INR and prothrombin time. Monitor INR closely.
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity. Consider dose reduction or interruption of pantoprazole.
### Monitoring
* Electrolytes (magnesium, calcium, potassium) with long-term use.
* Bone mineral density with prolonged therapy.
* Signs and symptoms of *C. difficile* infection.
* INR if co-administered with warfarin.
### Clinical Pearls
* Administer oral formulations 30 minutes before a meal.
* For patients unable to swallow whole tablets, pantoprazole for delayed-release oral suspension is available.
* IV formulation is available for patients unable to take oral medications.
* Long-term PPI therapy is associated with increased risks; use the lowest effective dose for the shortest duration necessary.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and clinical guidelines for complete details and to verify accuracy before making treatment decisions.
